Company: LHI
Filing Date: 2025-05-23
Form Type: F-1
Source: 0001213900-25-046955
Chunk: 19

Company: Living Homeopathy International Ltd.
Filing Date: 2025-05-23
Form: F-1
Chunk 19
---
 of this prospectus.                                                                           |

<div align='center'>4</div>

Risks Related to Our Corporate Structure We are also subject to risks and uncertainties related to our corporate structure, including, but not limited to, the following:

| ● | Our                                                                                          
 directors and officers currently own a significant percentage of the total voting power of   
 our outstanding  Ordinary Shares, and they collectively are able to decide matters           
 that require votes of shareholders. See more detailed discussion of this risk factor on page 
 26 of this prospectus.                                                                       |

| ● | You                                                                                         
 may face difficulties in protecting your interests, and your ability to protect your rights 
 through U.S. courts may be limited, because we are incorporated under Cayman Islands law.   
 See more detailed discussion of this risk factor on page 26 of this prospectus.             |

| ● | You                                                                                        
 may be unable to present proposals before annual general meetings or extraordinary general 
 meetings not called by shareholders. See more detailed discussion of this risk factor on   
 page 27 of this prospectus.                                                                |

| ● | Our directors are not                                                                                                                
 subject to a term of office. You may be unable to remove a director of the Company. See more detailed discussion of this risk factor 
 on page 27 of this prospectus.                                                                                                       |

| ● | Living                                                                                      
 Homeopathy may rely on dividends and other distributions on equity paid by its subsidiary   
 to fund any cash and financing requirements it may have, and any limitation on the ability  
 of Living Homeopath’s subsidiaries to make payments to it could have a material adverse     
 effect on Living Homeopathy’s ability to conduct its business. See more detailed discussion 
 of this risk factor on page 27 of this prospectus.                                          |

| ● | Living                                                                                     
 Homeopathy’s lack of effective internal controls over financial reporting may affect       
 its ability to accurately report its financial results or prevent fraud, which may affect  
 the market for and price of Living Homeopathy’s Class A Ordinary Shares. See more detailed 
 discussion of this risk factor on page 27 of this prospectus.                              |

| ● | If                                                                                           
 Living Homeopathy ceases to qualify as a foreign private issuer, it would be required to     
 comply fully with the reporting requirements of the Exchange Act applicable to U.S. domestic 
 issuers, and it would incur significant additional legal, accounting and other expenses that 
 it would not incur as a foreign private issuer. See more detailed discussion of this risk    
 factor on page 28 of this prospectus.